Antibodies to NTB-A
Anti-NTB-A antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind NTB-A and treat diseases, such as hematologic malignancies, which are characterized by expression of NTB-A.
1. An isolated antibody that specifically binds NTB-A or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable domain comprising the complementarity determining region (CDR) amino acid sequences of SEQ ID NO: 30, SEQ ID NO: 31, and SEQ ID NO: 32; and a light chain variable domain comprising the CDR amino acid sequences of SEQ ID NO:33, SEQ ID NO:34, and SEQ ID NO:35.
2. The antibody of claim 1 , wherein the heavy chain variable domain and the light chain variable domain are connected by a flexible linker to form a single chain antibody.
3. The antibody of claim 2 , which is an scFv antibody.
4. The antibody or antigen-binding fragment thereof of claim 1 , which is selected from the group consisting of a Fab antibody, a Fab′ antibody, a (Fab′) 2 antibody, a humanized antibody, and a chimeric antibody.
5. A pharmaceutical composition comprising an antibody of claim 1 , further comprising a suitable carrier.
6. A pharmaceutical composition comprising an antibody of claim 1 , further comprising at least one therapeutic agent.
7. An isolated cell line that produces the antibody according to claim 1 .
8. An isolated antibody that specifically binds NTB-A or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:9 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:11.
9. The antibody of claim 8 , wherein the heavy chain variable domain and the light chain variable domain are connected by a flexible linker to form a single chain antibody.
10. The antibody of claim 9 , which is an scFv antibody.
11. The antibody or antigen-binding fragment thereof of claim 8 , which is selected from the group consisting of a Fab antibody, a Fab′ antibody, a (Fab′) 2 antibody, a humanized antibody, and a chimeric antibody.
12. A pharmaceutical composition comprising an antibody of claim 8 , further comprising a suitable carrier.
13. A pharmaceutical composition comprising an antibody of claim 8 , further comprising at least one therapeutic agent.
14. An isolated cell line that produces the antibody according to claim 8 .
15. The antibody of claim 8 , wherein said antibody is murine anti-NTB-A monoclonal antibody 994.1 that is produced by a hybridoma having ATCC Deposit No. PTA7831.
16. The hybridoma cell line 994.1 deposited with the ATCC as accession number PTA7831.